HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yoo Jung Kim Selected Research

bazlitoran

4/2021A phase 2, double-blinded, placebo-controlled trial of toll-like receptor 7/8/9 antagonist, IMO-8400, in dermatomyositis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yoo Jung Kim Research Topics

Disease

2Neoplasms (Cancer)
02/2020 - 08/2004
1Dermatomyositis (Dermatopolymyositis)
04/2021
1Dermatitis
02/2020
1Breast Neoplasms (Breast Cancer)
02/2020
1Skin Diseases (Skin Disease)
02/2020
1Bronchiolitis Obliterans Syndrome
12/2019
1Abscess
06/2019
1Diphtheria
06/2019
1Granuloma
06/2019
1Inflammation (Inflammations)
06/2019
1Tetanus
06/2019
1Whooping Cough (Pertussis)
06/2019
1Blue Nevus
06/2019
1Body Weight (Weight, Body)
01/2008

Drug/Important Bio-Agent (IBA)

1bazlitoranIBA
04/2021
1Toll-Like Receptor 7IBA
04/2021
1Anastrozole (Arimidex)FDA LinkGeneric
02/2020
1Aromatase InhibitorsIBA
02/2020
1Estrogen ReceptorsIBA
02/2020
1Pertussis VaccineIBA
06/2019
1VaccinesIBA
06/2019
1IsoflavonesIBA
01/2008

Therapy/Procedure

2Radiotherapy
02/2020 - 08/2004
1Cell Transplantation
12/2019
1Drug Therapy (Chemotherapy)
08/2004